The Joint Stock Forecast, Price & News

+1.60 (+3.11 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $53.00
50-Day Range
MA: $44.23
52-Week Range
Now: $53.00
Volume238,270 shs
Average Volume160,512 shs
Market Capitalization$749.42 million
P/E Ratio196.30
Dividend YieldN/A
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2020, the company operated approximately 515 clinics operated or managed by franchisees and 64 company-owned or managed clinics in the United States. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
The Joint logo

Industry, Sector and Symbol

Industry Patent owners & lessors
Current SymbolNASDAQ:JYNT
Year FoundedN/A



Sales & Book Value

Annual Sales$48.45 million
Cash Flow$0.70 per share
Book Value$0.41 per share


Net Income$3.32 million


Market Cap$749.42 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


The Joint (NASDAQ:JYNT) Sets New 52-Week High at $50.38
April 9, 2021 |
The Joint (NASDAQ:JYNT) PT Raised to $57.00 at DA Davidson
April 7, 2021 |
The Joint (NASDAQ:JYNT) Stock Price Up 3.1%
April 7, 2021 |
The Joint Stock Appears To Be Significantly Overvalued
March 24, 2021 |
The Joint Corp. (JYNT) Q4 Earnings Lag Estimates
March 4, 2021 |
Joint's Earnings: A Preview
March 3, 2021 |
Is Joint (NASDAQ:JYNT) Using Too Much Debt?
March 1, 2021 |
The Joint Corp. to Participate in Upcoming Conferences
February 25, 2021 |
See More Headlines


Overall MarketRank

1.26 out of 5 stars

Medical Sector

860th out of 2,016 stocks

Patent Owners & Lessors Industry

7th out of 28 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+1.60 (+3.11 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

The Joint (NASDAQ:JYNT) Frequently Asked Questions

Is The Joint a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for The Joint in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" The Joint stock.
View analyst ratings for The Joint
or view top-rated stocks.

What stocks does MarketBeat like better than The Joint?

Wall Street analysts have given The Joint a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but The Joint wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is The Joint's next earnings date?

The Joint is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for The Joint

How were The Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings results on Wednesday, March, 3rd. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.14 by $0.58. The firm earned $17.04 million during the quarter, compared to analyst estimates of $16.64 million. The Joint had a trailing twelve-month return on equity of 51.77% and a net margin of 6.89%.
View The Joint's earnings history

How has The Joint's stock price been impacted by Coronavirus (COVID-19)?

The Joint's stock was trading at $13.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, JYNT stock has increased by 289.4% and is now trading at $53.00.
View which stocks have been most impacted by COVID-19

What guidance has The Joint issued on next quarter's earnings?

The Joint issued an update on its FY 2021 After-Hours earnings guidance on Thursday, March, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $73-77 million, compared to the consensus revenue estimate of $72.23 million.

What price target have analysts set for JYNT?

5 Wall Street analysts have issued 1 year price targets for The Joint's shares. Their forecasts range from $38.00 to $60.00. On average, they expect The Joint's share price to reach $51.20 in the next twelve months. This suggests that the stock has a possible downside of 3.4%.
View analysts' price targets for The Joint
or view top-rated stocks among Wall Street analysts.

Who are The Joint's key executives?

The Joint's management team includes the following people:
  • Mr. Peter D. Holt, CEO, Pres & Director (Age 62, Pay $666.57k)
  • Jake Singleton, Chief Financial Officer (Age 39, Pay $303.41k)
  • Mr. Jorge Armenteros, VP of Operations
  • Dr. Steven Knauf, Director of Chiropractic & Compliance
  • Mr. Jason Greenwood, VP of Marketing
  • Ms. Amy Karroum, VP of HR
  • Mr. Craig P. Colmar, Sec. (Age 68)
  • Mr. Eric Simon, VP of Franchise Sales & Devel.
  • Mr. David Glover, Regional Developer for West Lake Hills
  • Mr. Richard Matthews, Director of Real Estate Research

What is Peter D. Holt's approval rating as The Joint's CEO?

87 employees have rated The Joint CEO Peter D. Holt on Peter D. Holt has an approval rating of 59% among The Joint's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of The Joint's key competitors?

What other stocks do shareholders of The Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did The Joint IPO?

(JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is The Joint's stock symbol?

The Joint trades on the NASDAQ under the ticker symbol "JYNT."

How do I buy shares of The Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is The Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $53.00.

How much money does The Joint make?

The Joint has a market capitalization of $749.42 million and generates $48.45 million in revenue each year. The company earns $3.32 million in net income (profit) each year or $0.23 on an earnings per share basis.

How many employees does The Joint have?

The Joint employs 225 workers across the globe.

What is The Joint's official website?

The official website for The Joint is

Where are The Joint's headquarters?

The Joint is headquartered at 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260.

How can I contact The Joint?

The Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.